Table 1: Baseline characteristics and clinically relevant variables of 107 study patients.

VariableOne-year survivors 
( )
One-year nonsurvivors 
( )
value

Age (yrs)64.9 ± 13.162.9 ± 11.20.393
Male gender % ( )42.9% (24)72.5% (37)0.002
Body mass index (kg/m2) 22.8 ± 3.522.8 ± 3.00.986
History of smoking % ( )41.1% (23)54.9% (28)0.127
Hypertension % ( )54.9% (7)23.5% (12)0.135
Diabetes mellitus % ( )7.1% (4)13.7% (7)0.341
Red blood cell count (×106/dL)4.1 ± 0.64.0 ± 0.70.514
White blood cell count (×103/dL)7.30 ± 2.558.17 ± 3.480.135
Platelet count (×104/dL)22.99 ± 8.9125.59 ± 11.600.189
Creatinine (mg/dL)1.06 ± 0.690.99 ± 0.430.487
AST (IU/L)48.93 ± 26.6643.55 ± 23.260.106
ALT (IU/L)47.00 ± 22.7440.65 ± 17.060.267
First-line adjunctive therapy % ( )
 Concurrent chemoradiotherapy8.9% (5)15.7% (8)0.378
 Traditional chemotherapy50% (28)66.7% (34)0.116
 Target therapy41.1% (23)17.6% (9)0.011
Distant metastasis % ( )64.3% (36)70.6% (36)0.542
Stage % ( )1.000
 IIIb17.9% (10)17.6% (9)
 IV82.1% (46)82.3% (42)
Cell type % ( )0.134
 squamous cell carcinoma21.4% (12)35.3% (18)
 nonsquamous cell carcinoma78.6% (44)64.7% (33)
Metastatic site % ( )
 Pleura16.1% (9)23.5% (12)0.336
 Lung19.6% (11)21.6% (11)0.813
 Bone32.1% (18)21.4% (16)1.000
 Liver3.6% (2)17.6% (9)0.023
 Adrenal gland0% (0)2.0% (1)0.468
 Brain10.7% (6)23.5% (12)0.075
First-line treatment status % ( )0.017
 disease control75.0% (42)51.0% (26)
 disease progression25.0% (14)49.0% (25)
Performance Status % ( )0.042
 023.2% (13)25.5% (13)
 175.0% (42)60.8% (31)
 21.8% (1)13.7% (7)
Charlson comorbidity index 6.8 ± 2.37.7 ± 1.90.027

Data expressed as mean ± SD or % ( ) of patients.
AST: aspartate aminotransferase; ALT: alanine aminotransferase.